Sec Form 4 Filing - Bartushak Jaime @ Citius Pharmaceuticals, Inc. - 2023-10-10

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Bartushak Jaime 2. Issuer Name and Ticker or Trading Symbol Citius Pharmaceuticals, Inc. [ CTXR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Financial Officer (Last) (First) (Middle) C/O CITIUS PHARMACEUTICALS, INC., 11 COMMERCE DRIVE, FIRST FLOOR 3. Date of Earliest Transaction (MM/DD/YY) 10/10/2023 (Street) CRANFORD, NJ07016 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 60,353 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Purchase Common Stock) ( 1 ) $ 0.7 10/10/2023 A 300,000 ( 1 ) 10/10/2033 Common Stock 300,000 $ 0 300,000 D Stock Option (Right to Purchase Common Stock) ( 2 ) $ 1.25 ( 2 ) 10/04/2032 Common Stock 300,000 300,000 D Stock Option (Right to Purchase Common Stock) ( 3 ) $ 2.04 ( 3 ) 10/11/2031 Common Stock 300,000 300,000 D Stock Option (Right to Purchase Common Stock) ( 4 ) $ 2 ( 4 ) 07/22/2031 Common Stock 100,000 100,000 D Stock Option (Right to Purchase Common Stock) ( 5 ) $ 1.01 ( 5 ) 10/06/2030 Common Stock 125,000 125,000 D Stock Option (Right to Purchase Common Stock) ( 6 ) $ 0.67 ( 6 ) 10/08/2029 Common Stock 100,000 100,000 D Stock Option (Right to Purchase Common Stock) ( 7 ) $ 1.62 ( 7 ) 09/04/2028 Common Stock 70,000 70,000 D Stock Option (Right to Purchase Common Stock) ( 8 ) $ 3.45 ( 8 ) 09/15/2027 Common Stock 25,000 25,000 D Stock Option (Right to Purchase Common Stock) ( 9 ) $ 10.5 ( 9 ) 07/06/2026 Common Stock 48,267 48,267 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Bartushak Jaime C/O CITIUS PHARMACEUTICALS, INC. 11 COMMERCE DRIVE, FIRST FLOOR CRANFORD, NJ07016 Chief Financial Officer Signatures /s/ Alexander M. Donaldson, by power of attorney 10/12/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The options were granted on October 10, 2023. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company on each such vesting date. ( 2 )The options were granted on October 4, 2022. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company on each such vesting date. ( 3 )The options were granted on October 11, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company on each such vesting date. ( 4 )The options were granted on July 22, 2021. The options will vest 1/3 on each of the one-year, two-year and three-year anniversary of the Vesting Commencement Date, provided that the Optionee provides Continuous Service to the Company on each such vesting date. ( 5 )The options vested in full on October 6, 2023. ( 6 )The options vested in full on October 8, 2022. ( 7 )The options vested in full on September 4, 2021. ( 8 )the options vested in full on September 12, 2020. ( 9 )The options vested in full on July 7, 2019.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S .C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.